{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreibnzxseeuvylye7kvbi6pblcvupz5fnwan5rof3dbry2ny2rjh4hq",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mkpyexejmgh2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidws6x73nlbiiu5ubhfhy2ufhyqta2taqq3lvgogzje2nj7e5nfwe"
    },
    "mimeType": "image/jpeg",
    "size": 68765
  },
  "path": "/pharmalot/2026/04/30/fda-weight-loss-drugs-new-rule-would-end-glp-1-compound-pharmacy/?utm_campaign=rss",
  "publishedAt": "2026-04-30T15:53:39.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Business",
    "Health",
    "Health tech",
    "Pharma",
    "Pharmalot",
    "Politics",
    "Compounding",
    "drug development",
    "FDA",
    "Obesity",
    "Pharmaceuticals",
    "Policy",
    "STAT+",
    "weightloss"
  ],
  "textContent": "FDA moves to remove semaglutide, tirzepatide, and liraglutide from its 503B compounding list, saying there's no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.",
  "title": "STAT+: FDA wants to exclude weight-loss drugs from a compounding list",
  "updatedAt": "2026-04-30T16:00:18.000Z"
}